146 related articles for article (PubMed ID: 16143062)
1. [The proliferation, phenotype change and anti-tumor activity of cytokine induced killer cells].
Cao JP; Jiang ZM; Zhang XC; Lin D; Chen W; Sun YH; Ma DC
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 Sep; 21(5):583-6. PubMed ID: 16143062
[TBL] [Abstract][Full Text] [Related]
2. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
[TBL] [Abstract][Full Text] [Related]
3. [Autologous CIK cell infusion promotes amplification ability of CD3⁺ CD56⁺ cells when re-preparation from patients with malignant tumors].
Yu H; Sun Y; Lin D; Li C; Chen W; Ma D
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):748-53, 758. PubMed ID: 25001943
[TBL] [Abstract][Full Text] [Related]
4. The dual-functional capability of cytokine-induced killer cells and application in tumor immunology.
Zhang Q; Liu XY; Zhang T; Zhang XF; Zhao L; Long F; Liu ZK; Wang EH
Hum Immunol; 2015 May; 76(5):385-91. PubMed ID: 25305457
[TBL] [Abstract][Full Text] [Related]
5. [Killing activity of co-cultured cytokine-induced killer cells and dendritic cells against multi-drug resistant tumor cell lines].
Li SJ; Zhang LS; Chai Y; Zhang YF; Zhang YM; Zeng PY; Wu CY
Zhonghua Zhong Liu Za Zhi; 2007 Oct; 29(10):733-7. PubMed ID: 18396683
[TBL] [Abstract][Full Text] [Related]
6. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo.
Wang Y; Bo J; Dai HR; Lu XC; Lv HY; Yang B; Wang T; Han WD
Exp Hematol; 2013 Mar; 41(3):241-52.e3. PubMed ID: 23123634
[TBL] [Abstract][Full Text] [Related]
7. Comparative study on anti-tumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK.
Wang QJ; Wang H; Pan K; Li YQ; Huang LX; Chen SP; He J; Ke ML; Zhao JJ; Li JJ; Sun JC; Liang XT; Ma HQ; Chen YB; Xia JC
Chin J Cancer; 2010 Jul; 29(7):641-8. PubMed ID: 20591215
[TBL] [Abstract][Full Text] [Related]
8. CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses.
Zhu BQ; Ju SW; Shu YQ
Biomed Pharmacother; 2009 Aug; 63(7):509-16. PubMed ID: 19019623
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.
Schmidt-Wolf IG; Lefterova P; Mehta BA; Fernandez LP; Huhn D; Blume KG; Weissman IL; Negrin RS
Exp Hematol; 1993 Dec; 21(13):1673-9. PubMed ID: 7694868
[TBL] [Abstract][Full Text] [Related]
10. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo.
Huang J; Li C; Wang Y; Lv H; Guo Y; Dai H; Wicha MS; Chang AE; Li Q
Clin Immunol; 2013 Oct; 149(1):156-68. PubMed ID: 23994769
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model.
Kim HM; Kang JS; Lim J; Kim JY; Kim YJ; Lee SJ; Song S; Hong JT; Kim Y; Han SB
Arch Pharm Res; 2009 May; 32(5):781-7. PubMed ID: 19471894
[TBL] [Abstract][Full Text] [Related]
12. [Effects of autologous plasma and gentamicin on immunophenotype and viability of cytokine-induced killer cells].
Cao J; Yin W; Chen C; Luo X
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Sep; 30(9):906-8. PubMed ID: 25200150
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor effects of cocultured dendritic cells and cytokine-induced killer cells on lung cancer in vitro and in vivo].
Yang XJ; Huang JA; Lei W; Zhu YB; Zhang XG
Ai Zheng; 2006 Nov; 25(11):1329-33. PubMed ID: 17094896
[TBL] [Abstract][Full Text] [Related]
14. [Influence of albumin and placement time outside the incubator on viability of isolated cytokine-induced killer cells: a simple method for detection].
Pan C
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jul; 33(7):1078-82. PubMed ID: 23895858
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic characterization and anti-tumor effects of cytokine-induced killer cells derived from cord blood.
Zhang Z; Zhao X; Zhang T; Wang L; Yang L; Huang L; Li F; Liu J; Yue D; Wang F; Li J; Guan F; Xu Y; Zhang B; Zhang Y
Cytotherapy; 2015 Jan; 17(1):86-97. PubMed ID: 25457278
[TBL] [Abstract][Full Text] [Related]
16. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD56+ cells and downregulating regulatory T cells as well as IL-35.
Tao Q; Chen T; Tao L; Wang H; Pan Y; Xiong S; Zhai Z
J Immunother; 2013; 36(9):462-7. PubMed ID: 24145357
[TBL] [Abstract][Full Text] [Related]
17. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.
Franceschetti M; Pievani A; Borleri G; Vago L; Fleischhauer K; Golay J; Introna M
Exp Hematol; 2009 May; 37(5):616-628.e2. PubMed ID: 19375652
[TBL] [Abstract][Full Text] [Related]
18. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
Lu PH; Negrin RS
J Immunol; 1994 Aug; 153(4):1687-96. PubMed ID: 7519209
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation.
Wang W; Qin S; Zhao L
Biomed Pharmacother; 2015 Feb; 69():18-23. PubMed ID: 25661332
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway.
Iudicone P; Fioravanti D; Cicchetti E; Zizzari IG; Pandolfi A; Scocchera R; Fazzina R; Pierelli L
Hum Immunol; 2016 Dec; 77(12):1239-1247. PubMed ID: 27615504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
